151 related articles for article (PubMed ID: 38451524)
1. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
[TBL] [Abstract][Full Text] [Related]
3. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
Wu Y; Hu L; Zhang S; Zhang H
Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Liao PF; Wang PY; Peng TR
Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T
Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.
Ren W; Fang Y; He Y; Ren Y; Wang M; Xu A; Ruan J; Tao Q
Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38840327
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Antibodies Plus Chemotherapy as First-Line Treatment for NSCLC in the People's Republic of China: a Systematic Review and Meta-Analysis.
Chen QA; Ma K; Zhang L; Lin WH; Wu XX; Gao YB
JTO Clin Res Rep; 2024 Jun; 5(6):100678. PubMed ID: 38846810
[TBL] [Abstract][Full Text] [Related]
8. Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.
Chaft JE; Dziadziuszko R; Haddock Lobo Goulart B
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432500. PubMed ID: 38788177
[TBL] [Abstract][Full Text] [Related]
9. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Sathiyapalan A; Baloush Z; Ellis PM
Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
[TBL] [Abstract][Full Text] [Related]
10. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract][Full Text] [Related]
11. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
O'Brien J; Bodor JN
Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
[TBL] [Abstract][Full Text] [Related]
12. Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.
Ramamurthy C; Wheeler KM; Trecarten S; Hassouneh Z; Ji N; Lee Y; Svatek RS; Mukherjee N
J Cancer Immunol (Wilmington); 2024; 6(1):29-39. PubMed ID: 38784962
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis.
Dong HJ; Yang CY
Clin Respir J; 2024 May; 18(5):e13756. PubMed ID: 38725310
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of different cycles of neoadjuvant immunotherapy in resectable non-small cell lung cancer: A systematic review and meta-analysis.
Ye L; Liu Y; Xiang X; Wang Z; Peng W; Wei X; Zhang S; Xue Q; Zhou Q
Heliyon; 2024 Jun; 10(11):e31549. PubMed ID: 38828349
[TBL] [Abstract][Full Text] [Related]
15. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
Waser NA; Quintana M; Schweikert B; Chaft JE; Berry L; Adam A; Vo L; Penrod JR; Fiore J; Berry DA; Goring S
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38521542
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract][Full Text] [Related]
18. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis.
Hoff CO; Manzi J; Lazar Neto F; Ferrarotto R
JAMA Otolaryngol Head Neck Surg; 2024 May; ():. PubMed ID: 38814585
[TBL] [Abstract][Full Text] [Related]
19. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.
Efil SC; Bilgin B; Ceylan F; Karakaş H; Karahan İ; Özsan SN; Kosku H; Yaman Ş; Bülent Akıncı M; Dede DŞ; Yalçın B; Nahit Şendur MA
J Oncol Pharm Pract; 2024 Jun; ():10781552241260864. PubMed ID: 38860323
[TBL] [Abstract][Full Text] [Related]
20. Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials.
Zhou S; Horita N; Shao T; Harrington M; Fujiwara Y
Ther Adv Med Oncol; 2024; 16():17588359241257874. PubMed ID: 38845790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
